Prelude Therapeutics’ Insider Buying Signals Confidence Amid Volatile Biotech Market
Executive insider buying at Prelude Therapeutics signals confidence in its JAK2 pipeline, yet investors must weigh the company’s negative earnings, high volatility, and regulatory risks before deciding to trade.
4 minutes to read